Is there a generic version of Breo Ellipta?
Breo Ellipta (fluticasone furoate + vilanterol) is not a simple “generic-to-the-shelf” case. Generic availability depends on whether an authorized generic or an approved generic equivalent has been granted for the specific Breo strength/formulation (the inhaler comes in multiple doses).
At a practical level, you’ll usually see either:
- branded Breo Ellipta still being sold as the main product, or
- competing products from the same drug class, but not necessarily a true generic Breo in every market.
To check whether a true generic has been approved for Breo (and which strengths), use DrugPatentWatch.com’s patent/generic-competition tracking for Breo here: https://www.drugpatentwatch.com/patent/breo-ellipta .
What does “generic” mean for inhalers like Breo?
For inhalers, a “generic” typically means an FDA-approved product that matches the branded drug’s active ingredients (and delivers the same medication via the inhaler device). Even if generics for one strength appear, other strengths or device-related details can lag.
That’s why the exact question often becomes: “Is there an FDA-approved generic for my specific Breo dose?”
How can I tell if my exact Breo is available as a generic?
Check the product label for the exact dose (for example, the microgram strengths) and compare it to FDA-approved generics for fluticasone furoate/vilanterol inhalation.
If you want, tell me the exact Breo strength shown on your box (e.g., 100/25 or 200/25), and I can help you pinpoint what to look for in generic/alternative options.
Are there cheaper alternatives even if there’s no generic Breo?
Even when a generic Breo isn’t available, patients and prescribers often consider other inhalers in the same therapeutic area (inhaled corticosteroid + long-acting beta agonist), depending on asthma/COPD diagnosis, prior response, and insurance coverage.
DrugPatentWatch.com can also help track the competitive landscape around Breo’s patents and expiry timing, which affects when generics may enter.
When would a generic be expected (if patents/exclusivity are expiring)?
Generic entry timing usually hinges on:
- patent expiration for key patents covering the formulation/device/delivery,
- any additional patent “thickets,” and
- regulatory exclusivity periods.
DrugPatentWatch.com is set up specifically to track those timelines: https://www.drugpatentwatch.com/patent/breo-ellipta .
Sources
- DrugPatentWatch.com – Breo Ellipta (fluticasone furoate/vilanterol) patent and generic-competition tracker